イルミナ経営陣

イルミナに入社する前は、Agilentの上級副社長と、Agilentの市場をリードする分析機器ポートフォリオ、インフォマティクス、細胞解析フランチャイズで構成されるAgilent Life Sciences and Applied Markets Group（LSAG）の社長を務めていました。2014年から2018年までは、AgilentのDiagnostics and Genomics Group（DGG）の社長を務めていました。

Agilentに入社する前は、デンマークのがん診断会社DakoのR&D担当副社長でした。Dakoに入社する前は、Copenhagen Consultancy Company（現Bain & Co）で経営コンサルタントを務めていました。キャリアの初期には、デンマークに拠点を置く研究・防衛アプリケーション開発会社であるCantionの創設者兼最高技術責任者でした。

Thaysen氏は、デンマーク工科大学で物理学のMScとPhDを取得しています。

Steve Barnard, PhDはイルミナの最高技術責任者です。彼は、エンジニアリング、消耗品、アプリケーション、ユーザーデザイン、ソフトウェア、インフォマティクス、人工知能、科学関連、およびグローバル先進科学における、イルミナの研究および製品開発チームを率いています。これらのチームはイルミナのイノベーションエンジンであり、次世代シーケンサープラットフォームとアプリケーションにおいて優れた製品を提供し、科学のブレークスルーとゲノミクスの臨床への応用を促進します。

Dr. Barnardは、1998年に、最初のサイエンティストおよび4人目の従業員としてイルミナに入社し、輝かしい25年の在職期間を通して、イルミナのR&D部門でさまざまな指導的地位に就いていました。研究と技術開発における重要な役割を通して、Dr. Barnardは、合成化学、タンパク質工学、表面科学、アッセイ研究、ナノファブリケーションを含むイルミナの基礎科学技術の成熟に大きく貢献しました。100件以上の特許を世界中で取得しており、 分析化学、自然、科学、ゲノム研究など、さまざまな業界トップの科学雑誌に発表されています。

Dr. Barnardは、革新的なNovaSeq Xシリーズの発売など、業界をリードするイルミナ製品の進歩において重要な役割を果たしてきました。彼のイルミナのコアテクノロジーに対する深い理解は、R&Dの生産性と効率性を加速し、株主価値を推進しています。

Todd Christian is Head of Services, Arrays, and Genomics Access (SAGA) at Illumina, where he is responsible for the go-to-market strategy and commercialization of arrays, pharma and clinical diagnostics partnerships, Population Genomics, Services and Support, and Illumina Lab Services.

Before joining Illumina, Christian was vice president and general manager of the cell analysis division at Agilent Technologies, Inc. During his time there, he was an integral part of the company’s multi-year growth strategy to expand its position in cell analysis and other high-growth segments of the life sciences, biopharma and diagnostics markets to serve new and existing customers.

Christian is a distinguished leader in the life sciences market, with more than 25 years of experience in the industry. Before joining Agilent, he spent a number of years at both large and small organizations in the life sciences space, including Becton Dickinson, Applied Bioscience, and Guava Technologies.

He holds a Bachelor of Arts from Hamilton College and a variety of executive certificate programs in marketing, program management, and operations. He has recently served on a variety of non-profit boards focused on funding youth education and underserved communities, and actively volunteers with Habitat for Humanity.

As interim General Counsel and Secretary, Scott Davies has worldwide responsibility for all legal and intellectual property matters and regulatory and government affairs. He also serves as Illumina's code of ethics compliance officer.

Prior to his appointment as interim General Counsel and Secretary, Davies served as Illumina’s Vice President, Legal – Chief Corporate Counsel and Assistant Secretary. Davies joined Illumina in 2009 as its first corporate-focused attorney and has managed all of Illumina’s significant corporate legal matters and transactions since that time. While taking on positions of increasing responsibility, Davies developed and led a global corporate and commercial legal team and has worked closely with Illumina’s senior executive team and board of directors on a wide range of legal matters across the spectrum of Illumina’s global business operations.

Prior to joining Illumina, Davies was a corporate transactions (M&A), securities, and finance attorney for 12 years, including 10 years with Gibson, Dunn & Crutcher LLP, a leading international law firm, and two years with Allen & Overy, a leading UK-based global law firm, resident in its London office.

Davies received a J.D. from Cornell Law School and a B.A. from Brigham Young University.

As Chief Financial Officer (CFO), Ankur Dhingra is responsible for Illumina’s accounting, financial planning and analysis, internal audit, investor relations, tax, and treasury functions.

Prior to joining Illumina, Dhingra served as CFO at Summit Therapeutics – a California-based biopharmaceutical oncology company. He was previously CFO at CareDx, Inc, a molecular diagnostics company focused on the transplant patient journey. Dhingra spent 18 years at Agilent Technologies in a variety of financial and operational leadership roles, including Vice President of Investor Relations and Group CFO for the Life Sciences and Applied Markets Group (LSAG), which consists of Agilent's market leading analytical instrument portfolio, informatics, and cell analysis franchise.

Mr. Dhingra is a Chartered Accountant from The Institute of Chartered Accountants of India.

Mark Field joined Illumina as Chief Information Officer on May 29, 2025, bringing over two decades of experience in leading transformative technology initiatives across the life sciences and healthcare sectors. Prior to this role, he served as Chief Technology Officer at Insulet Corporation, where he was instrumental in the development and launch of the Omnipod® 5, the first tubeless automated insulin delivery system. Under his leadership, Omnipod® 5 achieved significant market success, contributing to Insulet's annual revenue surpassing $2 billion and serving approximately 500,000 patients worldwide.

Before his tenure at Insulet, Field held the position of Chief Technology Officer at Thermo Fisher Scientific. There, he led a global team responsible for IoT-connected device programs, cloud-based scientific services, and e-commerce, overseeing 54 business units. He was pivotal in developing the Thermo Fisher Cloud, a platform that revolutionized data sharing among scientists globally. Field's career also includes 17 years at Oracle Corporation, where he rose to Vice President and successfully led the integration of over 105 acquisitions.

Field holds a Bachelor of Science in Computer Science and a Bachelor of Commerce in Management and Information Systems from the University of Auckland in New Zealand. His extensive experience in regulated medical technology environments and his commitment to patient-centric design make him a valuable addition to Illumina's leadership team. As CIO, Field is poised to drive Illumina's digital transformation efforts, leveraging his global perspective and innovative approach to technology to enhance operational excellence and market leadership.

Pat Leckmanはイルミナの最高人事責任者で、同社の人事戦略のあらゆる側面を担当しています。Leckmanは、従業員の変革を主導し、ビジネスの成長を促進し、影響力の大きいチームを結成した実績があります。

それ以前は、Watson Wyatt、NVIDIA、Cisco、Perot Systemsなどのダイナミックな組織で働いていました。イルミナの人事リーダーシップチームの一員として在職中、報酬、福利厚生、人事テクノロジーの各部門を変革しました。契約やジョイントベンチャーを設計、契約、実施する国際チームを率いてきました。キャリアを通して、ビジネスプロセスの再設計、ベンダー評価、アウトソーシング、および移行管理においてクライアントを支援してきました。

Leckmanは、ロンドンビジネススクールで経営学の修士号を取得し、スタンフォード大学でコミュニケーションの学士号を取得しています。

Rami Mehio is the Senior Vice President, General Manager, BioInsight at Illumina. He is responsible for leading the research and development teams for bioinformatics, software, clinical interpretation and AI, as well as managing data partnerships, pharma collaborations, and national genomics initiatives. These teams deliver industry-leading solutions for genomic and multiomic applications, working closely with partners and customers to build, analyze, and monetize large datasets—leveraging them to develop new AI models and advance deep biological insights.

Mehio joined Illumina in 2018 through the acquisition of Edico Genome, where he led the development of the DRAGEN™ Bio-IT platform. He would later serve as Vice President and Head of Software and Informatics, where he drove Illumina’s software and informatics strategy across the company’s entire product portfolio, include instruments, cloud data platforms, and bioinformatics solutions.

Since joining Illumina, Mehio has played a pivotal role in establishing the company’s informatics offering as a comprehensive, end-to-end suite, including DRAGEN, Emedgene, ICA, and ICI products. Other key highlights under his leadership including the development of the COVIDSeq test, processing 500,000 UK Biobank samples, winning the PrecisionFDA challenge, and supporting the launch of NovaSeq, NextSeq 2000, and iSeq 100 sequencers.

Mehio holds both a Master of Science and a Bachelor of Science in Engineering from McGill University, and holds 166 global patents.

Kevin Pegels氏はイルミナのグローバルオペレーションチーフで、同社のグローバルオペレーションを担当しています。彼の組織には、製造、サプライチェーン、ライフサイクル管理、情報テクノロジー、グローバル施設、不動産の各チームが含まれ、これらのチームは高い製品品質と顧客満足度の確保に尽力しています。

イルミナに入社する前は、Bayer Healthcare、The Clorox Company、Levi Straussのサプライチェーンおよびオペレーション組織を率いる上級管理職に、20年以上従事していました。さらに、Deloitte Consultingでは、サプライチェーン、オペレーション戦略、プロセス改善について企業に助言を提供していました。

Kevin氏は現在、Bio Supply Management Alliance（BSMA）の諮問委員会のメンバーであり、San Diego Regional EDCの役員に就任する予定です。彼は、コーネル大学で化学工学のB.S.を、ハーバードビジネススクールでMBAを取得しています。

Jakob Wedel is Chief Strategy and Corporate Development Officer at Illumina, leading corporate strategy, partnerships, alliances, and acquisitions. With more than 25 years in top-tier strategy consulting focused on the life science and technology sector, Mr. Wedel brings a wealth of expertise in driving growth and innovation to the company.

Prior to joining Illumina, Wedel was a Senior Partner at Ernst and Young's strategy practice, EY Parthenon, where he played a key role in the global expansion of its life science strategy practice. His leadership in the global life science practice provided him with deep insights into the dynamics of the life science tools, clinical diagnostics and biopharma sectors, and positioned him as a trusted advisor for global industry executives.

Wedel spent more than 20 years at renowned consulting firms McKinsey and Bain & Co. serving life science, diagnostics and pharmaceutical clients in the US and Europe. He co-founded the Nordic strategy firm Qvartz, which grew to 450 professionals before being acquired by Bain.

Wedel attended Aarhus University in Denmark and earned a Master of Science in International Marketing & Management from Copenhagen Business School.

Conor McNamara, CFA, is Head of Investor Relations at Illumina, a role he assumed in September 2025.

Prior to joining Illumina, Conor was an Equity Research Analyst at RBC Capital Markets, where he covered the Life Science Tools & Diagnostics sector, including Illumina. From 2005 to 2021, he held analyst and portfolio manager roles at three investment firms – FrontPoint, Hudson Bay, and Tamarack – where he focused on the life sciences sector. Earlier in his career, Conor worked in investment banking and M&A advisory at Lehman Brothers and Deloitte, and in corporate development at McKesson.

Conor is a Chartered Financial Analyst (CFA) and holds a Bachelor of Arts degree in Economics from Occidental College.